Promising survival in patients with high-grade gliomas following therapy with a novel boronated porphyrin

Journal of Clinical Neuroscience

Volumn 10, Issue 4, 2003, Pages 425-427

  Rosenthal, Mark A ^a,b   Kavar, Bhadu ^c   Uren, Shannon ^a,b   Kaye, Andrew H ^c  

^a Centre for Development of Cancer Therapeutics   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Glioma; Photodynamic therapy

Indexed keywords

BORONOPORPHYRIN DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLIOBLASTOMA; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 0037696058     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0967-5868(03)00062-6     Document Type: Article

References (16)

1. American Cancer Society, SEER Statistics. 1999.
2. Surawicz T, McCarthy B, Kupelian V et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. Neuro-Oncology 1999; 1: 14-25.
3. Burger PC, Vogel FS, Green SB et al. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 1985; 56: 1106-1111.
4. Walker MD, Green SB, Byar DP et al. Randomised comparisons of radiotherapy and nitrosureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303: 1323-1329.
5. Levin VA. Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading. Neuro-Oncology 1999; 1: 69-80.
6. Kaye A, Hill JS. Photodynamic therapy of cerebral tumours. Neurosurg Quarter 1992; 1: 233-258.
7. Popovic EA, Kaye AH, Hill JS. Photodynamic therapy of brain tumours. Semin Surg Oncol 1995; 11: 335-345.
8. Rosenthal MA, Kavar B, Hill JS et al. Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin. J Clin Oncol 2001; 19: 519-524.
9. Hill JS, Kahl SB, Kaye AH et al. Selective tumour uptake of a boronated porphyrin in an animal model of cerebral glioma. Proc Natl Acad Sci USA 1992: 1785-1789.
10. Hill JS, Kaye AH, Kahl SB et al. Uptake of photosensitises into cerebral glioma. In: Spinelli P, Dal Fante M, Marchesini R (eds) Photodynamics therapy and biomedical lasers. Elsevier Science Publishers BV, Amsterdam 1992: 370-374.
11. Rosenthal MA, Gruber M, Glass J et al. Combination Taxol and Estramustine Phosphate in the treatment of malignant glioma. J Neuroonc 2000; 47: 59-63.
12. Harris M, Rosenthal MA, Ashley D, Cher L. An Australian experience with Temozolomide for the treatment of recurrent high-grade glioma. J Clin Neurosci 2000; 8: 325-327.
13. Levin VA. Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading. Neuro-Oncology 2000; 1: 69-80.
14. Wong E, Hess KR, Gleason MI et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 2001; 17: 2572-2578.
15. Yung A, Levin VA, Albright R et al. Randomised trial of temodal versus procarbazine in glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-593.
16. Yung WK, Prados M, Yaya-Tur R, Rosenfeld S et al. Multicenter Phase II Trial of Temozolomide in patients with Anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999; 17: 2762-2771.